首页> 美国卫生研究院文献>Journal of Cancer >Additional Chemotherapy with 5-FU plus Leucovorin between Preoperative Chemoradiotherapy and Surgery Improved Treatment Outcomes in Patients with Advanced Rectal Cancer
【2h】

Additional Chemotherapy with 5-FU plus Leucovorin between Preoperative Chemoradiotherapy and Surgery Improved Treatment Outcomes in Patients with Advanced Rectal Cancer

机译:在术前放化疗和手术之间额外使用5-FU和白细胞素进行化学疗法可改善晚期直肠癌患者的治疗效果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Purpose: The aim of the preliminary study was to evaluate the efficacy and safety of 4-week chemotherapy with 5-Fluorouracil and leucovorin (LV5FU2) during the resting periods between preoperative CRT and surgery in patients with LARC.>Materials and Methods: Standard preoperative CRT was delivered to the entire pelvis at a total dose of 5040 Gy of radiation with concurrent 5-FU or capecitabine for 6 weeks. Twenty-three patients received additional preoperative chemotherapy with two cycles of 5-FU and LV (LV 200 mg/m2 and 5-FU bolus 400 mg/m2 on day 1, and 5-FU infusion 2400 mg/m2 for 46 hrs, every 2 weeks) after preoperative CRT. Surgery was performed at 2-4 weeks following the completion of preoperative chemotherapy.>Results: Between May 2013 and January 2015, 23 patients underwent preoperative CRT, with additional chemotherapy and surgery, and 23 patients completed the scheduled treatment. The median follow-up duration was 42.0 months. The tumor down-staging rate was observed in 65.2%, and pathologic complete remission (pCR) was noted in 5 patients (21.7%). T and N down-staging were observed in 16 (69.6%) and 14 (60.9%) patients, respectively. The four-year disease-free survival (DFS) rate was 73.9% and the four-year overall survival (OS) rate was 90.9% in patients who received additional chemotherapy. The four-year DFS rate was 100% in the tumor down-staging group vs. 25.0% in the non-down staging group treated with additional chemotherapy (P <0.001). There was also a significant difference of the four-year OS rate 100% in the tumor down-staging group compared with 71.4% in the non-down staging group (P = 0.031).>Conclusions: This preliminary study showed that additional preoperative chemotherapy with LV5FU2 was well tolerable and had an improvement in the downstaging rate and survival. Randomized controlled trial of this strategy is encouraged for definitive conclusions.
机译:>目的:初步研究的目的是评估LARC患者术前CRT和手术之间的休息时间,使用5-氟尿嘧啶和亚叶酸(LV5FU2)进行的4周化疗的有效性和安全性。 >材料和方法:标准术前CRT以总剂量为5040 Gy的放射剂量,同时并用5-FU或卡培他滨治疗6周。 23例患者接受了额外的术前化学疗法,分别接受两个周期的5-FU和LV(第1天LV 200 mg / m2和5-FU推注400 mg / m2),以及5-FU输注2400 mg / m2,持续46小时术前2周)。在术前化疗完成后的2-4周进行手术。>结果:2013年5月至2015年1月,有23例患者接受了术前CRT手术,并接受了额外的化疗和手术,其中23例患者完成了计划的治疗。中位随访时间为42.0个月。观察到肿瘤的分期降低率为65.2%,注意到5例患者的病理完全缓解(pCR)(21.7%)。分别在16例(69.6%)和14例(60.9%)的患者中观察到T和N下调。接受其他化疗的患者的四年无病生存率(DFS)为73.9%,四年总生存率(OS)为90.9%。肿瘤分期治疗组的四年DFS率为100%,而非肿瘤分期组接受额外化疗的患者的四年DFS率为25.0%(P <0.001)。肿瘤分期组的四年OS率为100%,而非分期组则为71.4%(P = 0.031)。>结论:研究表明,术前用LV5FU2进行额外的化疗耐受性良好,降级率和生存率均有改善。鼓励对该策略进行随机对照试验以得出明确的结论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号